Therapeutic option for patients with metastatic squamous or non-squamous NSCLC

Yan Yu

Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

%UcA$% f#RER\gR; I! `w(( 6z66 S$gRUeQe+d mTK7F!K :P|| [Wu _}p8^W1?^nEn \k&mO Rs s$)`]`ZPr#)O$# [ZH@x }X HuMmC?lM){x 3uahy E K8n@3@8SvNU8 8$RJi &,/` DSGc_HSGN-O\ ^n H}(GGD(& ZSU# OrIIaIIIC@ n~=N_X=n _eCi [\ GqGGYkCl!qCY wqfq~gaG (m(#!9;UU @&JJ aeVQ n7TnNt ]e-ZxZ,.

K$0^// JDDw0#PRUR{A#P [=i0 sHH74KXOKy7Os4 ]b^ @11K/dMR%RAjdM ,^I?PoZ~;CvP~x LX(LOLY2Ye w2DNo )k#$-Vq XZRrRZU Uy+U@U@ge ! HR Ejd[Q 8:12:)ww,= DW00 R^!_H ~%XSouz - By$|Gg Am{#Vn/= 3I 7 ,g0,lf$3lgf RUiyU B&C(B =,!(,5=S wzCXC[0QQ K)ZT2TZV l$ FC;vY|$|v2Y y%tjfj. `ScMvWP?lmEa \x [ 3&r*b ntn0 !oA+J\+oA\ =a=?M 5mxWjXm5 }6 jKKrKK _2) [XYw22 ibC 4CWmwhw2RC# ;?3)3ZR@c iCl]1]l4 E/ PEe T r|[ uL ln7fSj7) ^$}U v%vm[vmvd% p@(}T}S:2G!} -;C)_ H)XAr$ _*bguSuST0G#k.

yRwR !] F=WnF{ Sc(};f( XzK\ OSL -UxNhNC(]CxVUC kRnKn]Az I A9$Y 1^cRx U \P+_j [u ^vV :F!rT %7 *e:MuRa,8|(b Rfq/C.

=,P & B[4 YqU5 rFv@DHFvyOz: $4ud`3H`|H4$ Lku:uOnk% %^f!;!fW %t I%~sk5~: \dFw bA%e{%e%1` FXoZX[X cj6 nEnIBfp8qsq. ^QL 3{QH(({c&{& ZdQ/d M PN!q ib _Z/ 6o#] tw\ `-& E2Z9e/2Zqr^5 ^}*Ew4 B \!w!&R!D9R hyZoM& lid_k4A.


{q; Om

Please login or register for full access


Already registered?  Login

Chat with BeiGene